NCT03629756 : A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Breast,Female reproductive organs,Head and neck,Lung,Skin,Stomach and upper gastrointestinal tract,Urinary systemBladder,Breast,Colorectum,Endometrium,Gastro-oesophageal junction ,Head and neck,Kidney,Lung,Melanoma (Skin),Merkel cell,Non-Small Cell Lung Cancer,Ovary,Renal cell carcinoma,Squamous cell carcinoma

Trial Overview Read MoreRead more

This phase I trial is evaluating the combination of two immunotherapy drugs (AB928 and AB122) in patients with certain types of advanced cancer.
 

This trial is treating patients with advanced cancers.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Commercial Sponsor

Arcus Biosciences, Inc.

Summary

This is a dose escalation and expansion trial, evaluating an escalating and selected dose of oral AB298 in combination with intravenous AB122.

Recruiting Hospitals Read MoreRead more

Cabrini Education and Research Precinct
Malvern
Li Hoon Lai
lihoonlai@cabrini.com.au
(03) 9508 3421

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next